search
Back to results

Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.

Primary Purpose

Acne Vulgaris, LASER

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
LASER MILESMAN 445 NM
Sponsored by
Gaias Salud
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris focused on measuring LASER, ACNÉ, MILESMAN

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults between 18 and 50 years old
  • Diagnosis of mild to moderate acne on the face
  • They must have 10 - 50 inflammatory lesions (papules and pustules) on the face
  • In general good health

Exclusion Criteria:

  • Allergies or light sensitivities.
  • Severe acne or pre-existing dermatological facial condition
  • Presence of cysts on the face
  • More than one nodule on the face
  • Having an uncontrolled disease or an immunodeficient disorder.
  • Being pregnant or lactating
  • Oral and / or topical antibiotic treatment in the last 2 weeks.
  • Current treatment with hormonal contraceptives.
  • Impossibility of avoiding excessive sun exposure and any light treatment or any similar pro-fessional or aesthetic procedure during the 15 days before and 15 days after treatment.
  • Previous history of poorly healed wounds, keloid formation, or bleeding disorders
  • Process of active or historical infection of herpes simplex.
  • Extreme sensitivity to hydroquinone or other bleaching agents.
  • Personal or family history of melanoma.
  • Dysplastic nevus.

Sites / Locations

  • GAIAS RESEARCH,C/PINTOR XAIME QUESADA Nº3

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Laser application ( BEFORE/AFTER)

Arm Description

All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself. The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study.

Outcomes

Primary Outcome Measures

How many lesions treated have disappeared
Number of lesions before laser vs. number of lesions after laser(72 h and 1 week ).

Secondary Outcome Measures

Number of participants with treatment-related adverse events as assessed by MedRA
The number of related adverse reactions is collected and cataloged.

Full Information

First Posted
October 6, 2020
Last Updated
March 11, 2021
Sponsor
Gaias Salud
Collaborators
Gaias Research
search

1. Study Identification

Unique Protocol Identification Number
NCT04698239
Brief Title
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
Official Title
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
September 24, 2020 (Actual)
Primary Completion Date
February 15, 2021 (Actual)
Study Completion Date
February 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gaias Salud
Collaborators
Gaias Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Acne treatment by laser or other light devices is a currently accepted procedure. It allows faster resolution of injuries, with fewer side effects and greater patient satisfaction. The mechanism of action of the Milesman Blauman laser is based on diode laser technology that produces pulses of blue light with a wavelength of 445 nanometers, in the blue and visible spectrum. It combines the precision of laser technology by focusing energy on diseased areas.
Detailed Description
Introduction / Justification Acne vulgaris (AV) is a polygenic multifactorial disease of the pilosebaceous units, which leads to the formation of both non-inflammatory lesions (comedones) and inflammatory lesions (papules, pustules, nodules and cysts), which affects approximately 85% of the population . Acne treatment by laser or other light devices is a currently accepted procedure. It allows faster resolution of injuries, with fewer side effects and greater patient satisfaction. The mechanism of action of the Milesman Blauman laser is based on diode laser technology that produces pulses of blue light with a wavelength of 445 nanometers, in the blue and visible spectrum. It combines the precision of laser technology by focusing energy on diseased areas. The MILESMAN Laser has been on the market for over two years and has been used for cosmetic purposes and has proven to be safe during that time on the market. MAIN GOAL The main objective of this study is to describe the efficacy and safety of the device (Milesman Laser) as a treatment for inflammatory acne lesions (papules and pustules). To do this, we will measure the evolution of the number of injuries of this type on the patient, before and after the application of the laser. EXPLORATORY OBJECTIVES Additionally, the study will have the following objectives: Exploratory assessment of the change in acne classification on the EGAE scale (grade 1 - 4) after laser application. Evaluate the adverse effects derived after the laser application. Evaluate the degree of patient satisfaction after the laser application. STUDY DESIGN Open, prospective, interventional, single-arm, quasi-experimental analytical study of before and after. This type of design is based on the measurement and comparison of the response variable before and after the subject's exposure to the experimental intervention. It is a national, single-center study. SAMPLE SIZE According to the objective of the study, we plan to get at least 25 patients. In this study we define sample as the entire area to be treated on the face, that is, we will obtain 25 samples. STUDY PERIOD The duration of the study will be 3 months from the inclusion of the first patient. The duration of the patient in the study is 14 days. DESCRIPTION OF THE INTERVENTION The Milesman laser has a handpiece, which allows each injury to be targeted via an indicator light and the person handling it will trigger the shot via a foot pedal. A maximum of 10 shots will be made on each acne injury, depending on the size and type of injury. Finally, 2-3 shots will be taken to photocoagulate the follicle walls and thus prevent the lesion from recurring or becoming infected again. The laser will be applied to all inflammatory facial injuries in a single session, it is estimated that the duration of the session is about 20 minutes, depending on the number of injuries

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris, LASER
Keywords
LASER, ACNÉ, MILESMAN

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Laser application ( BEFORE/AFTER)
Arm Type
Experimental
Arm Description
All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself. The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study.
Intervention Type
Device
Intervention Name(s)
LASER MILESMAN 445 NM
Intervention Description
Laser application
Primary Outcome Measure Information:
Title
How many lesions treated have disappeared
Description
Number of lesions before laser vs. number of lesions after laser(72 h and 1 week ).
Time Frame
1 week
Secondary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by MedRA
Description
The number of related adverse reactions is collected and cataloged.
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults between 18 and 50 years old Diagnosis of mild to moderate acne on the face They must have 10 - 50 inflammatory lesions (papules and pustules) on the face In general good health Exclusion Criteria: Allergies or light sensitivities. Severe acne or pre-existing dermatological facial condition Presence of cysts on the face More than one nodule on the face Having an uncontrolled disease or an immunodeficient disorder. Being pregnant or lactating Oral and / or topical antibiotic treatment in the last 2 weeks. Current treatment with hormonal contraceptives. Impossibility of avoiding excessive sun exposure and any light treatment or any similar pro-fessional or aesthetic procedure during the 15 days before and 15 days after treatment. Previous history of poorly healed wounds, keloid formation, or bleeding disorders Process of active or historical infection of herpes simplex. Extreme sensitivity to hydroquinone or other bleaching agents. Personal or family history of melanoma. Dysplastic nevus.
Facility Information:
Facility Name
GAIAS RESEARCH,C/PINTOR XAIME QUESADA Nº3
City
Santiago de Compostela
State/Province
La Coruña
ZIP/Postal Code
15702
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.

We'll reach out to this number within 24 hrs